1105 related articles for article (PubMed ID: 12757558)
1. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.
Feldman H; Gauthier S; Hecker J; Vellas B; Emir B; Mastey V; Subbiah P;
J Am Geriatr Soc; 2003 Jun; 51(6):737-44. PubMed ID: 12757558
[TBL] [Abstract][Full Text] [Related]
2. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
[TBL] [Abstract][Full Text] [Related]
4. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Ames D; Subbiah P; Whalen E; Emir B;
Int Psychogeriatr; 2002 Dec; 14(4):389-404. PubMed ID: 12670060
[TBL] [Abstract][Full Text] [Related]
6. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease.
Gauthier S; Lopez OL; Waldemar G; Jones RW; Cummings J; Zhang R; Schindler R; Schwam E
Int Psychogeriatr; 2010 Sep; 22(6):973-83. PubMed ID: 20534179
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
10. Impact of donepezil treatment for Alzheimer's disease on caregiver time.
Wimo A; Winblad B; Shah SN; Chin W; Zhang R; McRae T
Curr Med Res Opin; 2004 Aug; 20(8):1221-5. PubMed ID: 15324524
[TBL] [Abstract][Full Text] [Related]
11. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
12. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
13. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
14. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
[TBL] [Abstract][Full Text] [Related]
15. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
16. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
Hashimoto M; Yatabe Y; Kaneda K; Honda K; Ikeda M
Psychogeriatrics; 2009 Dec; 9(4):196-203. PubMed ID: 20377821
[TBL] [Abstract][Full Text] [Related]
17. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
[TBL] [Abstract][Full Text] [Related]
18. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
Wimo A; Winblad B; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Mastey V; Haglund A; Zhang R; Miceli R; Chin W; Subbiah P;
Dement Geriatr Cogn Disord; 2003; 15(1):44-54. PubMed ID: 12457078
[TBL] [Abstract][Full Text] [Related]
19. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
20. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
